Grace Halsey

Nearly 40% of perimenopausal women report misdiagnosis as clinicians treat for anxiety and depression without addressing underlying hormonal imbalance.

The comprehensive timeline highlights how WHI findings and subsequent research reshaped HRT risk assessment, guidance, and FDA labeling through 2025.

A geriatric psychiatrist's clinical pearls on agitation in AD, incluiding behavioral cues, triggers, and evidence-based treatment strategies for primary care.

A 10-year microsimlation model of annual MCED testing revealed signficant reductions in late-stage cancer diagnoses, particularly for cancers lacking routine screening,

Many caregivers, both paid and unpaid, miss or misinterpret agitation symptoms in Alzheimer disease, fueling stress, stigma, and delayed medical support.

Mitchell highlights hormone therapy prescribing for primary care: treatment algorithms, vaginal estrogen safety, and when progestins aren't needed.

Research reveals metformin's potential to enhance sinus rhythm stability post-ablation for AF in adults with obesity, independent of weight loss.

Indiana University study found that integrating patient-reported outcome questionnaires with machine learning boosts dementia diagnoses by 31% in primary care settings.

The TARGET-D trial found targeted vitamin D dosing post-MI didn’t lower MACE but reduced recurrent MI risk, supporting individualized serum-level management.

Recognize Cushing syndrome in primary care: key clinical clusters, first-line screening tests (DST, salivary cortisol, UFC), and when to refer to endocrinology.

Sublingual epinephrine film matches adult PK/PD in kids aged 7-17 with a history of allergic reactions and high risk for serious allergic reactions, incluing anaphylaxis.

Merck's oral PCSK9 inhibitor enlicitide demonstrated antibody-like LDL-C lowering in adutls with HeFH with safety profile similar to placebo in phase 3 trial.

Phase 2b findings show rezpegaldesleukin reduced ACQ-5 scores and improved key AD endpoints in participants with comorbid asthma.

Submission of the sNDA suggests a potential FDA decision on the dextromethorphan-bupropion combination sometime during the first quarter of 2026.

Nearly 40% of REDEFINE 1 participants taking antihypertensive medications reduced or discontinued their blood pressure drugs during the trial, Novo Nordisk reported.

Adults with diabetes often face obstacles to optimal disease management in the workplace. Use this checklist in the clinic to help them navigate the barriers.

TMS 2025: Dr Marla Shapiro doesn't start perimenopausal therapy without an answer to the most important question: "What is your most bothersome symptom?"

Trump announces deals with Eli Lilly and Novo Nordisk slashing GLP-1 prices to as low as $150/month, expanding Medicare coverage starting mid-2026.

Oral semaglutide 25 mg improved glucose control and CV risk factors across weight loss categories in OASIS 4 post hoc analysis presented at ObesityWeek 2025.

As adjunctive treatment, lumateperone is associated with early symptom improvement, good tolerability, and provides a practical no-titration option for adults with persistent MDD.

New longitudinal data from a Korean cohort suggest OSA may be an independent risk factor for cerebral small vessel disease.

Novel AD therapies targeting OX40, IL-13, IL-36, IL-22, and IL-2 pathways show promise for disease modification and extended dosing intervals in phase 2-3 trials.

Global survey data highlight persistent stigma and self-management barriers for adults with diabetes in the workplace, with implications for clinical care.

Patient preferences favor home-based tests but MDs do not, while cost barriers significantly impact follow-up completion, according to the 2 new analyses.

These 42 factors that affect blood glucose are in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.

Women experience greater CR mortality benefits than men yet have 36% lower enrollment. New AHA statement addresses barriers across the care continuum.

"If you don't know where your keys are, that's fine." Shapiro's memorable analogy helps distinguish perimenopause brain fog from serious cognitive concerns.

The real-world study of 200,000+ adults found no GI safety differences among 3 GLP-1 drugs for T2D, however SGLT-2 inhibitors are safer for motility issues.

WAYFINDER: 90% of steroid-dependent severe asthma patients reduced to ≤5mg daily on tezepelumab. Well-controlled asthma increased from 3% to 27% at 52 weeks.

Three-biomarker panel independently predicted cardiovascular events over 20 years in European cohort, with highest risk when all 3 were elevated.